Filed Pursuant to Rule 424(b)(3)
Registration No. 333-257202
The information in this preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed.
Preliminary Prospectus Supplement
Subject to Completion, dated February 16, 2023
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated June 21, 2021)
7,000,000 SHARES
COMMON STOCK
Essential Properties Realty Trust, Inc.
We expect to enter into forward sale agreements with each of BofA Securities, Inc., Citibank, N.A. and Wells Fargo Securities, LLC, which we refer to in this capacity as the forward purchasers. In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow from third parties and to sell to the underwriters an aggregate of 7,000,000 shares of our common stock, $0.01 par value per share, of our common stock (or an aggregate of 8,050,000 shares of our common stock if the underwriters’ option to purchase additional shares is exercised in full) that will be delivered in this offering.
We will not receive any proceeds from the sale of shares of our common stock by the forward purchasers. We expect to physically settle the forward sale agreements (by the delivery of shares of our common stock) and receive proceeds from the sale of those shares of our common stock upon one or more forward settlement dates, which we anticipate will be within approximately 12 months from the date of this prospectus supplement. We may also elect to cash settle or net share settle all or a portion of our obligations under a forward sale agreement if we conclude it is in our best interest to do so. If we elect to cash settle a forward sale agreement, then we may not receive any proceeds and may owe cash to the relevant forward purchaser in certain circumstances. If we elect to net share settle a forward sale agreement, then we will not receive any proceeds and may owe shares of our common stock to the relevant forward purchaser in certain circumstances. See “Underwriting—Forward Sale Agreements.”
If any forward purchaser or its affiliate does not deliver and sell all of the shares of our common stock to be delivered and sold by it on the anticipated closing date of this offering, then we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that such forward purchaser or its affiliate did not sell, and the number of shares underlying the relevant forward sale agreement will be decreased by the number of shares that we issue and sell.
Our common stock is listed on the New York Stock Exchange, or the NYSE, under the symbol “EPRT.” On February 15, 2023, the last sale price of our common stock as reported on the NYSE was $24.88 per share.
We elected to qualify as a real estate investment trust, or REIT, for federal income tax purposes commencing with our taxable year ended December 31, 2018. To assist us in maintaining our qualification for taxation as a REIT for U.S. federal income tax purposes, and other reasons, subject to certain exceptions, no person may own more than 9.8%, in value or in number of shares, whichever is more restrictive, of our outstanding shares of our common stock, or 9.8% in value of the aggregate of the outstanding shares of our capital stock. You should read the information under the section entitled “Prospectus Supplement Summary—Ownership Limit” in this prospectus supplement and “Restrictions on Ownership and Transfer” in the accompanying prospectus for a description of these and other restrictions on ownership and transfer of our stock.
Investing in our common stock involves risks. You should read carefully and consider the “Risk Factors” beginning on page S-6 of this prospectus supplement and the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2022, which is incorporated by reference herein, for factors you should consider before investing in our common stock.
Neither the Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | | | | | | | |
| | Per Share | | | Total | |
Public offering price | | $ | | | | $ | | |
Underwriting discounts and commissions(1) | | $ | | | | $ | | |
Proceeds, before expenses, to us (2) | | $ | | | | $ | | |
(1) | We refer you to “Underwriting” beginning on page S-12 of this prospectus supplement for additional information regarding underwriting compensation. |
(2) | We have assumed that the forward sale agreements will be fully physically settled based on the initial forward sale price of $ per share, which is the public offering price less the underwriting discounts and commissions shown above. The forward sale price is subject to adjustment pursuant to the terms of each forward sale agreement, and the actual proceeds, if any, to us will be calculated as described in this prospectus supplement. Although we expect to settle the forward sale agreements entirely by the full physical delivery of shares of our common stock in exchange for cash proceeds within 12 months from the date of this prospectus supplement, we may elect cash settlement or net share settlement for all or a portion of our obligations under any forward sale agreement. See “Underwriting—Forward Sale Agreements” for a description of the forward sale agreements. |
The underwriters have been granted a 30-day option from the date of this prospectus supplement, exercisable in whole or in part from time to time, to purchase up to an additional 1,050,000 shares of our common stock at the public offering price less the underwriting discounts and commissions. Upon any exercise of such option, we expect to enter into additional forward sale agreements with each forward purchaser in respect of the number of shares sold by the applicable forward purchaser or its affiliate in connection with the exercise of such option. Unless the context requires otherwise, the term “forward sale agreement” as used in this prospectus supplement includes any additional forward sale agreement that we enter into in connection with the exercise by the underwriters of their option to purchase additional shares. In such event, if any forward purchaser or its affiliate does not deliver and sell all of the shares of our common stock to be delivered and sold by it in connection with the exercise of such option, then we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that such forward purchaser or its affiliate did not sell, and the number of shares underlying the relevant additional forward sale agreement will be decreased by the number of shares that we issue and sell.
| | | | |
BofA Securities | | Citigroup | | Wells Fargo Securities |
The date of this prospectus supplement is February , 2023